Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 1997

View Archived Issues

Natural immunosuppressive agent disclosed by Kyowa Hakko

Kyowa Hakko discovers antitumor compounds in Streptomyces culture

Antimicrobial/cytotoxic compound isolated from fungal strain by Boehringer Mannheim

Novel antifibrillatory agent: DP-16

TAK-225 stimulates airways mucociliary transport

Rebamipide for diabetic nephropathy

Effects of thrombin inhibitor with or without gpIIb/IIIa antagonist during coronary thrombolysis

Orally active H3 receptor agonist prodrug with antiinflammatory/antinicoceptive properties

Roche's T-type calcium channel blocker receives European approval

Company profile: NexMed

FDA approves Mirapex for the treatment of Parkinson's disease

Company profile: NeoPharm

Company profile: GlycoDesign

Promising preliminary phase II results obtained for Protovir in bone marrow transplant patients

Hyal's treatment for sun spots approved in the U.K.

Encouraging phase I trial results reported with MDX-33

Shield Diagnostics acquires Murex subsidiary

ACT licenses rights to patents related to dendritic cell therapy

New cardiovascular gene therapy company launched in the U.K.

Emdogain approved in South Africa

Sugen files IND for angiogenesis inhibitor

BMS to develop products using CIMA's OraSolv oral delivery technology

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...